Evidence map›Paper›PMID 36047022›Full record

ReviewThe bone & joint journal2022

Prediction tools for the personalized management of soft-tissue sarcomas of the extremity.

Ibtissam Acem, Michiel A J van de Sande

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The bone & joint journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ibtissam AcemDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0002-8042-9856
Michiel A J van de SandeDepartment of Orthopaedic Oncology, Leiden University Medical Centre, Leiden, the Netherlands.ORCID 0000-0002-9156-7656

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prediction tools are instruments which are commonly used to estimate the prognosis in oncology and facilitate clinical decision-making in a more personalized manner. Their popularity is shown by the increasing numbers of prediction tools, which have been described in the medical literature. Many of these tools have been shown to be useful in the field of soft-tissue sarcoma of the extremities (eSTS). In this annotation, we aim to provide an overview of the available prediction tools for eSTS, provide an approach for clinicians to evaluate the performance and usefulness of the available tools for their own patients, and discuss their possible applications in the management of patients with an eSTS.Cite this article:

Indexed as

SarcomaSoft Tissue NeoplasmsExtremitiesHumansPrognosisRetrospective StudiesAdjuvant treatmentchemotherapycliniciansDecision curve analysisextremitiesExtremitiesModel performance(Neo)adjuvant chemotherapyNomogramoncologyPersonalized carePhysiciansPredictionsprognosisradiotherapysarcomasSoft-tissue sarcomaSoft-tissue sarcomas

Identifiers

PMID36047022
PMCPMC9987162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.